Top

Published in:

01-06-2016 | Original Article

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice

Authors: A. J. M. Beijers, G. Vreugdenhil, S. Oerlemans, M. Eurelings, M. C. Minnema, C. M. Eeltink, L. V. van de Poll-Franse, F. Mols

Published in: Supportive Care in Cancer | Issue 6/2016

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients’ health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MM patients.

Methods

One hundred fifty-six MM patients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response).

Results

The psychometric analyses showed a Cronbach’s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2–3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.

Conclusions

CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.

Available only for authorised users

Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al. (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22:417–426CrossRefPubMedPubMedCentral

Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, et al. (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311–319CrossRefPubMed

Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11:1086–1095CrossRefPubMed

Jongen JL, Broijl A, Sonneveld P (2015) Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neuro-Oncol 121:229–237CrossRef

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967CrossRefPubMed

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479–494CrossRefPubMed

Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454–462CrossRefPubMedPubMedCentral

Zweegman S, Lokhorst HM, Levin MD, Waal de E, Bos GMJ, Kersten MJ, et al. (2012) Guidelines for the treatment of multiple myeloma 2012. Ned Tijdschr Hematol 8:300–320

Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRefPubMed

10.

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744CrossRefPubMed

11.

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. (2006) Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 7:903–909CrossRefPubMed

12.

Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22:2261–2269CrossRefPubMed

13.

van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, et al. (2011) The Patient Reported Outcomes Following Initial Treatment and Long Term Evaluation Of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47:2188–2194CrossRefPubMed

14.

PHAROS. Population-based Haematological Registry for Observational Studies (PHAROS), http://www.pharosregistry.nl/. Accessed 1 June 2015

16.

Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139CrossRefPubMed

17.

Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741–748CrossRefPubMed

18.

Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. (2003) Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61:1297–1300CrossRefPubMed

19.

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15–49CrossRefPubMed

20.

Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, et al. (1996) Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 92:604–613CrossRefPubMed

21.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed

22.

Michielsen HJ, De Vries J, Van Heck GL (2003) Psychometric qualities of a brief self-rated fatigue measure: the fatigue assessment scale. J Psychosom Res 54:345–352CrossRefPubMed

23.

Nunnally JC (1978) Psychometric theory. McGraw-Hill, New York

24.

Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26:595–608CrossRefPubMed

25.

Babyak MA (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 66:411–421PubMed

26.

Burnand B, Kernan WN, Feinstein AR (1990) Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol 43:1273–1284CrossRefPubMed

27.

Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29:89–96CrossRefPubMed

28.

Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, et al. (2008) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 143:511–519PubMed

29.

Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, et al. (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24:976–982CrossRefPubMed

30.

Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manag 46:671–680CrossRef

31.

Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787–2799CrossRefPubMedPubMedCentral

32.

van der Poel MW, Oerlemans S, Schouten HC, van de Poll-Franse LV (2015) Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 94:651–661CrossRefPubMed

Title: Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice
Authors: A. J. M. Beijers
G. Vreugdenhil
S. Oerlemans
M. Eurelings
M. C. Minnema
C. M. Eeltink
L. V. van de Poll-Franse
F. Mols
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 6/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-3032-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2016

Predictors of quality of life in head and neck cancer survivors up to 5 years after end of treatment: a cross-sectional survey

Play-based procedural preparation and support intervention for cranial radiation

Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis

Winged scapula incidence and upper limb morbidity after surgery for breast cancer with axillary dissection

Effectiveness of acupuncture in rehabilitation of physical and functional disorders of women undergoing breast cancer surgery

Topical application of Aloe vera and vitamin E on induced ulcers on the tongue of rats subjected to radiation: clinical and histological evaluation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer